Medlab developed the nanoparticle medicine delivery system, Nanocelle.
Ltd (), a developer of cannabis based medicines, has made solid progress with its proprietary pain management product, Nanabis.
Nanabis is an Australian produced medicine made to Australian standards in an Australian approved facility and the in house developed Nanocelle, is a unique delivery system.
The medicine will be supported by trial data, giving prescribers confidence in quality and efficacy.
Medlab is developing therapies for pain management, depression and obesity, and it is already earning revenue from the sale of nutritional products in Australia and the US.
Nanocelle is an established delivery system
The Medlab developed nanoparticle medicine delivery system, Nanocelle, is already being applied to its medicines, nutritional products and off-patent drugs like statins.
The first batch of Nanabis product has been manufactured in Melbourne and validated analytical release for supply is expected by March 8, 2018.
Medlab approved as a supplier by Australian government
The Australian Government via the Office of Drug Control, has formally licenced Medlab as a supplier of Nanabis.
In keeping with the Therapeutic Goods Association’s special access scheme, Medlab has instituted medical education seminars to assist health professionals’ understanding.
On validation of the manufactured Nanabis product, Medlab will be in a position to supply a drug that conforms to Australian standards with proven quality and efficacy.
